Related Experiment Video

Updated: Jul 8, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Bortezomib inhibits osteoclast activity in patients with multiple myeloma

Geoffrey L Uy1, Rachna Trivedi, Shachar Peles

  • 1Section of Bone Marrow Transplant and Leukemia, Division of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Clinical Lymphoma & Myeloma
|January 12, 2008
PubMed
Abstract

Insights

Bortezomib, an antimyeloma drug, was found to suppress osteoclast activity in multiple myeloma patients. This bone-protective effect occurred independently of other treatments or disease markers.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Background:

  • Bortezomib is an antimyeloma agent that inhibits nuclear factor-kappaB (NF-kappaB).
  • NF-kappaB inhibition is theoretically linked to osteoclast function, but prior studies focused on osteoblasts.
  • The direct impact of bortezomib on osteoclasts requires further investigation.

Purpose of the Study:

  • To prospectively examine bone turnover markers in multiple myeloma patients undergoing bortezomib treatment.
  • To determine the effect of bortezomib on osteoclast function during and after autologous stem cell transplantation.
  • To assess if bortezomib's effects on bone are independent of bisphosphonates or monoclonal protein levels.

Main Methods:

  • Prospective analysis of bone turnover parameters in 39 multiple myeloma patients.
  • Bortezomib administration in two cycles before transplantation and as maintenance therapy post-transplantation.
  • Measurement of urinary collagen N-telopeptide to assess osteoclast activity.

Main Results:

  • A decrease in urinary collagen N-telopeptide excretion was observed during post-transplantation bortezomib therapy.
  • This reduction indicates that bortezomib effectively suppresses osteoclast function.
  • The observed effect on osteoclasts was independent of bisphosphonate use or changes in monoclonal protein levels.

Conclusions:

  • Bortezomib demonstrates a suppressive effect on osteoclast activity in multiple myeloma patients.
  • This bone-protective action occurs independently of other therapeutic interventions or disease progression markers.
  • Further research into bortezomib's potential as a bone-protective agent is warranted.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...